459 related articles for article (PubMed ID: 34585294)
1. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN
World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294
[TBL] [Abstract][Full Text] [Related]
2. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
[TBL] [Abstract][Full Text] [Related]
3. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
Mertens LS; Meijer RP; Meinhardt W; van der Poel HG; Bex A; Kerst JM; van der Heijden MS; Bergman AM; Horenblas S; van Rhijn BW
BJU Int; 2014 Jul; 114(1):67-74. PubMed ID: 24053889
[TBL] [Abstract][Full Text] [Related]
4. Determinants of adequate lymph node dissection following neoadjuvant chemotherapy in patients with urothelial muscle-invasive bladder cancer: results from the National Cancer Database.
Monaghan TF; Flores VX; Suss NR; Robins DJ; Smith MT; McNeil BK; Hyacinthe LM; Weiss JP; Winer AG
Int Urol Nephrol; 2021 Feb; 53(2):235-239. PubMed ID: 32865771
[TBL] [Abstract][Full Text] [Related]
5. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience.
Iyer G; Tully CM; Zabor EC; Bochner BH; Dalbagni G; Herr HW; Donat SM; Russo P; Ostrovnaya I; Regazzi AM; Milowsky MI; Rosenberg JE; Bajorin DF
Clin Genitourin Cancer; 2020 Oct; 18(5):387-394. PubMed ID: 32273235
[TBL] [Abstract][Full Text] [Related]
7. Variations in pelvic lymph node dissection in invasive bladder cancer: A Dutch nationwide population-based study during centralization of care.
Hermans TJ; Fransen van de Putte EE; Fossion LM; Werkhoven EV; Verhoeven RH; van Rhijn BW; Horenblas S
Urol Oncol; 2016 Dec; 34(12):532.e7-532.e12. PubMed ID: 27491835
[TBL] [Abstract][Full Text] [Related]
8. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival.
Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A
Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752
[No Abstract] [Full Text] [Related]
9. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A
World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
[TBL] [Abstract][Full Text] [Related]
10. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
11. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
[TBL] [Abstract][Full Text] [Related]
12. Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only.
Cajipe M; Wang H; Elshabrawy A; Kaushik D; Liss M; Svatek R; Wu S; Chowdhury WH; Ramamurthy C; Mansour AM
Urol Oncol; 2020 Apr; 38(4):231-239. PubMed ID: 31956078
[TBL] [Abstract][Full Text] [Related]
13. Impact of Variant Histology on Occult Nodal Metastasis after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Review of the National Cancer Database.
Fu M; Klose C; Sparks A; Whalen M
Clin Genitourin Cancer; 2022 Apr; 20(2):e135-e139. PubMed ID: 34961704
[TBL] [Abstract][Full Text] [Related]
14. Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.
Hwang EC; Sathianathen NJ; Imamura M; Kuntz GM; Risk MC; Dahm P
Cochrane Database Syst Rev; 2019 May; 5(5):CD013336. PubMed ID: 31111956
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder.
Park K; Lee HJ; Kim TU; Ryu H; Ki YK; Hong YJ; Nam JK
Asia Pac J Clin Oncol; 2023 Dec; 19(6):739-746. PubMed ID: 37461246
[TBL] [Abstract][Full Text] [Related]
16. Income Disparities in Survival and Receipt of Neoadjuvant Chemotherapy and Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer.
Antar RM; Xu VE; Adesanya O; Drouaud A; Longton N; Gordon O; Youssef K; Kfouri J; Azari S; Tafuri S; Goddard B; Whalen MJ
Curr Oncol; 2024 May; 31(5):2566-2581. PubMed ID: 38785473
[No Abstract] [Full Text] [Related]
17. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
[TBL] [Abstract][Full Text] [Related]
18. Preoperative chemotherapy in clinically node positive muscle invasive bladder cancer: Radiologic variables can predict response.
Ghodoussipour S; Xu W; Tran K; Atkinson R; Cho D; Miranda G; Cai J; Bhanvadia S; Schuckman A; Daneshmand S; Djaladat H
Urol Oncol; 2021 Feb; 39(2):133.e1-133.e8. PubMed ID: 32900621
[TBL] [Abstract][Full Text] [Related]
19. Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy.
Moschini M; Mattei A; Cornelius J; Shariat SF; Dell'Oglio P; Zaffuto E; Salonia A; Montorsi F; Briganti A; Colombo R; Gallina A
World J Urol; 2018 Apr; 36(4):639-644. PubMed ID: 29368231
[TBL] [Abstract][Full Text] [Related]
20. Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study.
Bruins HM; Skinner EC; Dorin RP; Ahmadi H; Djaladat H; Miranda G; Cai J; Daneshmand S
Urol Oncol; 2014 Jan; 32(1):24.e13-9. PubMed ID: 23395238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
